About Sahajanand Medical Technologies
Sahajanand Med Tech has registered for an initial public offering (IPO) in the amount of Rs.1,500 crore with SEBI. A fresh issuance of Rs.410.33 crore and an offer for the sale of equity shares worth Rs.1,089.67 crore are included in the IPO. Dhiraj Kumar S Vasoya is selling Rs.100 crore worth of shares, Shree Hari Trust is selling Rs.33.75 crore worth of shares, and Samara Capital Markets Holding is selling Rs.635.56 crore worth of shares, and NHPEA Sparkle Holding BV is selling Rs.320.36 crore worth of shares.
They are also mulling an Rs.185 crore pre-IPO placement. Axis Capital Ltd, BofA Securities India Ltd, Edelweiss Financial Services, and UBS Securities India Pvt Ltd are the book-running lead managers for this issuance.
Sahajanand Medical Tech was founded in 2001 and is a major medical device firm that specialises in the research, development, production, and marketing of vascular devices all over the world. In India, they maintained a 31 per cent market share in the drug-eluting stent market in FY21. As of March 31, 2021, Sahajanand was among the top five corporations in market share in nations such as Germany, the Netherlands, Poland, and Italy. They sell and distribute their products in 69 countries throughout the world. Interventional cardiology, structural heart treatment, and peripheral intervention are all areas where their products are employed. Surat, Galway, Ireland, and Nonthaburi, Thailand are the locations of their three research and development centres. Sahajanand Medical Technologies has received 67 patents worldwide, with 17 more patents in the works and four design registrations in India.